The Business Behind...
Health Care: Drugs
Gilead Sciences Inc (GILD: NASDAQ)
$56.47 0.73 | 1.31%
05/21/13 - 04:00 PM ET
Portfolios with GILD
- Portfolio NameUser Type
- ContributorMost-Active Stocks for the ...
- UserDC
- ProHighbridge Capital Management
- ProSteven Cohen - SAC Capital
- ProJohn Griffin - Blue Ridge C...
- UserMike Fatah's Mega Stock Por...
- UserRenzo's portfolio
- ContributorDrugs Facing FDA Approval i...
- UserGFNN Stockdiagnostics 23
- UserBender
Latest GILD Headlines from TheStreet
- Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 05.21.13 | 05:05 pm
- Cramer's Top Stock Picks: SAVE GILD BMY HTA TSLA 05.21.13 | 06:05 am
- 5 Stocks Underperforming Today In The Drugs Industry 05.20.13 | 01:05 pm
- Quick Take: The Next Big Thing in Biotech 05.17.13 | 10:05 am
- 'Mad Money' Lightning Round: Magnum Hunter Blew It 05.17.13 | 06:05 am
- Biotech's Next Big Thing ASCO II
05.16.13 | 02:05 pm - ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up 05.15.13 | 06:05 pm
- ASCO '13 Preview: Gilead's Big Cancer Debut 05.15.13 | 06:05 pm
- 5 Stocks Boosting The Drugs Industry Higher 05.15.13 | 01:05 pm
- Gilead Reaches New 52-Week High (GILD) 05.15.13 | 09:05 am
Press Releases for GILD
- Gilead Announces Update On Phase 3 Study Of Oral Fixed-Dose Combination Of Sofosbuvir And Ledipasvir For Genotype 1 Hepatitis C Patients - Business Wire 03.26.13 | 08:03 am
- European CHMP Adopts Positive Opinion For Stribild®, A Once-Daily, Integrase Inhibitor-Based, Single Tablet Regimen For The Treatment Of HIV-1 Infection - Business Wire 03.22.13 | 08:03 am
- Gilead’s Ranexa® Reduces Angina Frequency In Study Of Chronic Angina Patients With Type 2 Diabetes - Business Wire 03.10.13 | 02:03 pm
- Gilead Announces Full 24-Week Phase 2 Results For Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF) - Business Wire 03.05.13 | 12:03 pm
- Gilead Sciences To Present At The Cowen & Company 33rd Annual Health Care Conference On Monday, March 4 - Business Wire 03.01.13 | 04:03 pm
- Gilead Sciences To Present At Two Upcoming Investor Conferences - Business Wire 02.25.13 | 04:02 pm
- Gilead And Teva Reach Settlement Agreement In Viread® Patent Litigation - Business Wire 02.19.13 | 11:02 pm
- Gilead’s Sofosbuvir For Hepatitis C Meets Primary Endpoint In Fourth Pivotal Phase 3 Study - Business Wire 02.19.13 | 08:02 am
- Gilead Issues A Voluntary Recall Of One Lot Of Vistide® (Cidofovir Injection) Due To Presence Of Particulate Matter - Business Wire 02.15.13 | 06:02 pm
- Gilead Sciences To Present At Two Upcoming Investor Conferences - Business Wire 02.11.13 | 04:02 pm
Partner Headlines for GILD
- Will Influenza A H7N9 Generate Opportunities For Pharma? - Seeking Alpha 05.21.13 | 09:05 am
- Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 14, 2013 - NASDAQ 05.13.13 | 11:05 am
- Short Interest in Vertex Rises, in Celgene Falls - Benzinga 05.11.13 | 10:05 am
- Techne Corporation (TECH) Ex-Dividend Date Scheduled for May 08, 2013 - NASDAQ 05.07.13 | 01:05 pm
- Leading Biotechs Act Well But Be Careful Not To Chase - Investor's Business Daily 05.06.13 | 06:05 pm
- Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13) - Seeking Alpha 05.05.13 | 06:05 am
- Market Wrap for Friday, May 3: Stocks Jump on Strong Jobs Data - Benzinga 05.03.13 | 04:05 pm
- Inside Wall Street: closer to a cystic fibrosis cure - MSN Money 05.03.13 | 01:05 pm
- Stocks Maintain Early Momentum; Gilead Sciences, Neustar Surge - Investor's Business Daily 05.03.13 | 12:05 pm
- Stocks Rocket On Jobs Data; Fleetcor, Bonanza Creek Soar - Investor's Business Daily 05.03.13 | 10:05 am
